First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Amarex Clinical Research guides its client to phase II of FDA trials
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Cantourage introduces second Clever Leaves medical cannabis product to the German market
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Subscribe To Our Newsletter & Stay Updated
